1. PAH-Related Morbidity as a Predictor of Mortality

3. 2015 ESC/ERS Guidelines: Risk Assessment in PAH

4. A Multiparameter Risk Assessment Is Needed

5. ESC/ERS Guidelines: Assessment and Timing for Follow-Up of Patients With PAH

6. French Registry: BNP Subset Analysis

7. Prognostic Relevance of PAH-Related Morbidity

8. SERAPHIN and GRIPHON

9. Objective of the Landmark Analyses

10. Association Between Morbidity Before Month 3 and Mortality

11. Association Between Morbidity and Mortality at Any Landmark Time Point*

12. Morbidity Events in SERAPHIN and GRIPHON

13. GRIPHON: Association Between Individual Morbidity Components and Mortality

14. Importance of Thinking About the Future of Individual Patients
Importance of Thinking About the Future of Individual Patients...NOT the Past

15. Looking Ahead…

16. Importance of Achieving Low-Risk Status at Follow-Up

17. Summary of 3 European Studies

18. Initial Treatment Approaches to PAH

19. Evolving Treatment Paradigm

20. Concluding Remarks

21. Abbreviations

22. Abbreviations (cont)